Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Large‐scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels

9 Feb 2016

Abstract excerpt

Limitations of current diagnostic and prognostic tools for prostate cancer (PC) have led to over-diagnosis and over-treatment. Here, we investigate the biomarker potential of the SLC18A2 (VMAT2) gene for PC at three molecular levels. Thus, SLC18A2 promoter methylation was analyzed in 767 malignant and 78 benign radical prostatectomy (RP) samples using methylation-specific qPCR and Illumina 450K methylation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Lipids, and Metabolism
Share to Molecular Biology Techniques and Applications
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26905753
DOI: 10.1016/j.molonc.2016.02.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Large‐scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levelsPMID 26905753Read ↗

Prediction of Prognosis in Patients with Prostate Cancer by DNA Methylation ClassificationSemantic proximity Read ↗

A three‐gene DNA methylation biomarker accurately classifies early stage prostate cancerSemantic proximity Read ↗

Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patientsSemantic proximity Read ↗

Prognostic DNA Methylation Markers for Prostate CancerSemantic proximity Read ↗

Epigenome-wide DNA methylation and transcriptome profiling of localized and locally advanced prostate cancer: Uncovering new molecular markersSemantic proximity Read ↗

Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive diseaseSemantic proximity Read ↗

Development and Validation of MyProstateScore 2.0 to Detect Clinically Significant Prostate CancerSemantic proximity Read ↗

Genomic DNA Methylation-Derived Algorithm Enables Accurate Detection of Malignant Prostate TissuesSemantic proximity Read ↗

MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumorsSemantic proximity Read ↗

Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genesSemantic proximity Read ↗

Decipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patientsSemantic proximity Read ↗

Multi-omics approach for identifying CNV-associated lncRNA signatures with prognostic value in prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.